Omega Therapeutics, Inc. (OMGA)
| Market Cap | 876.54M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.52M |
| Shares Out | 46.62M |
| EPS (ttm) | -0.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,403 |
| Open | 19.98 |
| Previous Close | 19.91 |
| Day's Range | 18.76 - 21.14 |
| 52-Week Range | 15.50 - 24.29 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 29.50 (+56.9%) |
| Est. Earnings Date | Nov 15, 2021 |
About OMGA
At Omega Therapeutics, our goal is to pioneer a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to fundamentally transform human medicine in the service of patients. Our pioneering OMEGA Epigenomic Programming platform is designed to coopt nature’s universal operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. We rationally design and engineer modular, programmable mRNA-encoded epigenetic medicines, which we call Omega Epigenomic Controllers, or OECs, to target DNA-se...
Financial Performance
Financial StatementsNews
Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives
CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therape...
Omega Therapeutics Kicks Start Trading On NASDAQ
On the heels of a $126 million crossover round in March, Flagship Pioneering-backed Omega Therapeutics Inc (NASDAQ: OMGA) has priced a $125.8 million IPO to take its "epigenomic controllers" into the cl...
Omega Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass, July 29, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harne...
Omega Therapeutics IPO Registration Document (S-1)
Omega Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.